Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA grants orphan drug status to Ractigen’s RAG-18 for DMD and BMD
The saRNA product candidate is being developed for the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy. Credit: Michal Jarmoluk from Pixabay.
The saRNA product candidate is being developed for the treatment of Duchenne muscular dystrophy and Becker muscular dystrophy. Credit: Michal Jarmoluk from Pixabay.